Grant of PDMR Options
15/03/2022 13:49
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220315:nRSO8614Ea&default-theme=true
RNS Number : 8614E Instem plc 15 March 2022
Instem plc
("Instem" or "the Company")
Grant of PDMR Options
Instem plc (AIM: INS), a leading provider of IT solutions to the global life
sciences market, announces that Phil Reason (Chief Executive Officer) and
Nigel Goldsmith (Chief Financial Officer) have each been granted awards of
nil-cost options over 4,833 and 2,165 Ordinary Shares respectively under the
Instem plc 2018 Long Term Incentive Plan ("LTIP"). These options will
ordinarily vest and become exercisable on 1 January 2025 pursuant to the rules
of the LTIP.
After these grants of options, Mr Reason and Mr Goldsmith hold options
over a total of 133,649 and 261,696 Ordinary Shares, respectively.
For further information, please contact:
Instem plc via Walbrook
Singer Capital Markets (Nominated Adviser & Broker) +44 (0) 20 7496 3000
Peter Steel
Rachel Hayes
Alex Bond
Stifel Nicolaus Europe Limited (Joint Broker) +44 (0) 20 7710 7600
Ben Maddison
Alex Price
Walbrook Financial PR +44 (0) 20 7933 8780
Tom Cooper instem@walbrookpr.com
Nick Rome
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Phil Reason
2 Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification /Amendment Initial
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Instem plc
b) LEI 213800PILYUFNNROQX68
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Grant of nil cost options under the Company's LTIP
Identification code GB00B3TQCK30
b) Nature of the transaction Grant of nil cost options under the Company's LTIP
c) Price(s) and volume(s)
Price Volume(s)
Nil 4,833
d) Aggregated information
- Aggregated volume N/A - Single transaction
- Price
e) Date of the transaction 7(th) March 2022
f) Place of the transaction Off-market transaction
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Nigel Goldsmith
2 Reason for the notification
a) Position/status Chief Financial Officer
b) Initial notification /Amendment Initial
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Instem plc
b) LEI 213800PILYUFNNROQX68
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary shares of 10p each
Identification code GB00B3TQCK30
b) Nature of the transaction Grant of nil cost options under the Company's LTIP
c) Price(s) and volume(s)
Price(s) Volume(s)
Nil 2,165
d) Aggregated information N/A - Single Transaction
- Aggregated volume
- Price
e) Date of the transaction 11(th) March 2022
f) Place of the transaction Off-market transaction
About Instem
Instem is a leading provider of IT solutions & services to the life
sciences market delivering compelling solutions for Study Management,
Regulatory Submissions, Clinical Trial Acceleration, and Informatics-based
Insight Generation.
Instem solutions are in use by over 700 customers worldwide, including all of
the largest 25 pharmaceutical companies, enabling clients to bring life
enhancing products to market faster. Instem's portfolio of software solutions
increases client productivity by automating study-related processes while
offering the unique ability to generate new knowledge through the extraction
and harmonisation of actionable scientific information.
Instem products and services address aspects of the entire drug development
value chain, from discovery through to market launch. Management estimate that
over 50% of all drugs on the market have been through some part of Instem's
platform during their development.
To learn more about Instem solutions and its mission, please
visit www.instem.com (http://www.instem.com/)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHUVSORUAUOAAR